Over 500,000 nonmelanoma skin cancers are diagnosed and treated in this country each year. All treatment modalities quote a 90% or greater cure rate. Even with high cure rates, thousands of patients will require secondary treatment. Some nonmelanoma skin cancers are very aggressive and may not be resectable following single treatment failure. Recurrent tumors in critical anatomic locations require a multidisciplined approach. Combined tumor board evaluation and management are advocated.